Konrad H. Stopsack

Related Links

Biography

I am a molecular and clinical epidemiologist with a focus on cancer epidemiology and a background as a board-certified internal medicine physician. My main research interest is how potentially modifiable exposures cause solid tumors through genomic heterogeneity and influence cancer progression. I am passionate about combining well-defined observational studies and state-of-the-art genomics in order to guide cancer prevention and treatment. My methodologic and teaching interests include application and further development of epidemiologic methods for high-dimensional biomarker studies and clinical studies.

Education and Training

• MD, Medicine
  University of Freiburg
• MPH, Biostatistics and Epidemiology
  Harvard School of Public Health
• Residency, Board certification, Internal Medicine
  Mayo Clinic
• Postdoctoral training, Cancer Epidemiology
  Memorial Sloan Kettering Cancer Center

Publications

• A Gene Expression Tumor Signature Optimizing Partial Area-Under-the-Curve (pAUC) to Improve Specificity for Indolent Prostate Cancer.

  Gerke TA, Tyekucheva S, Stopsack KH, Sweeney CJ, Lis RT, Westling EN, Loda M, Stampfer MJ, Penney KL, Parmigiani G, Mucci LA. Prostate 2026

  PMID: 42053424

• Post-diagnostic Inflammatory and Insulinemic Diet and Lifestyle Patterns and Risk of Prostate Cancer-Specific Mortality in the Health Professionals Follow-up Study.

  Graff RE, Pace WA, Kenfield SA, Van Blarigan EL, Langlais CS, Ma C, Stopsack KH, Stampfer MJ, Giovannucci EL, Mucci LA, Tabung FK, Chan JM. Cancer Epidemiol Biomarkers Prev 2026 Apr 27

  PMID: 42043179

• Polygenic risk score and 20-year prostate cancer-specific mortality and survival.

  Plym A, Wang A, Stopsack KH, Zhang Y, Baras A. Commun Med (Lond) 2026 Apr 24

  PMID: 42032305

• Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.

  Bandlamudi C, Muldoon D, de Bruijn I, Zhang M, Gormally MV, Harrold EC, Nandakumar S, Smith SA, Jeng MY, Woods S, Arora K, Chatila WK, Nguyen B, Walch H, Woo J, Bielski CM, Fong C, Tran TN, Zhao G, Mehine M, Perry MA, Tischfield SE, Richards AL, Rajendran S, Zhang H, Kreitzer CK, Shah R, Huq R, Galle J, Alano T, Madupuri R, Kundra R, Jee J, Pichotta K, Waters M, Hickman RA, Dermawan JK, Chen JF, Safonov A, Stopsack KH, Kotecha RR, Rizvi HA, Friedman CF, Razavi P, Rosen E, Murciano-Goroff YR, Morris LGT, Fagin JA, Mellinghoff IK, Chi P, Shukla NN, Schoenfeld AJ, Riely GJ, Rudin CM, Drilon A, June-Koo Lee J, Al-Ahmadie HA, Iyer G, Varghese AM, O'Reilly EM, Stadler ZK, Robson ME, Reznik E, Gao J, Mandelker D, Ostrovnaya I, Rana S, Jayakumaran G, Bowman A, Mohanty A, Balakrishnan AR, Syed A, Ptashkin RN, Casanova-Murphy J, Chakravarty D, Benayed R, Arcila ME, Chandarlapaty S, Yu HA, Rosen N, Donoghue MTA, Klebanoff CA, Yaeger R, Brannon AR, Zehir A, Ladanyi M, Schultz N, Solit DB, Berger MF. Cancer Cell 2026 May 11

  PMID: 42001850

• Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.

  Bandlamudi C, Muldoon D, de Bruijn I, Zhang M, Gormally MV, Harrold EC, Nandakumar S, Smith SA, Jeng MY, Woods S, Arora K, Chatila WK, Nguyen B, Walch H, Woo J, Bielski CM, Fong C, Tran TN, Zhao G, Mehine M, Perry MA, Tischfield SE, Richards AL, Rajendran S, Zhang H, Kreitzer CK, Shah R, Huq R, Galle J, Alano T, Madupuri R, Kundra R, Jee J, Pichotta K, Waters M, Hickman RA, Dermawan JK, Chen JF, Safonov A, Stopsack KH, Kotecha RR, Rizvi HA, Friedman CF, Razavi P, Rosen E, Murciano-Goroff YR, Morris LGT, Fagin JA, Mellinghoff IK, Chi P, Shukla NN, Schoenfeld AJ, Riely GJ, Rudin CM, Drilon A, Lee JJ, Al-Ahmadie HA, Iyer G, Varghese AM, O'Reilly EM, Stadler ZK, Robson ME, Reznik E, Gao J, Mandelker D, Ostrovnaya I, Rana S, Jayakumaran G, Bowman A, Mohanty A, Balakrishnan AR, Syed A, Ptashkin RN, Casanova-Murphy J, Chakravarty D, Benayed R, Arcila ME, Chandarlapaty S, Yu HA, Rosen N, Donoghue MTA, Klebanoff CA, Yaeger R, Brannon AR, Zehir A, Ladanyi M, Schultz N, Solit DB, Berger MF. Cancer Cell 2026 May 11

  PMID: 41895280